Bendell, J. C., Hochster, H., Hart, L. L., Firdaus, I., Mace, J. R., McFarlane, J. J., Kozloff, M., Catenacci, D., Hsu, J. J., and Hack, S. P. (2017). A Phase II Randomized Trial (GO27827) of First‐Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer. The oncologist 22, 264-271.
Berlin, J., Bendell, J. C., Hart, L. L., Firdaus, I., Gore, I., Hermann, R. C., Mulcahy, M. F., Zalupski, M. M., Mackey, H. M., and Yauch, R. L. (2013). A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. Clinical Cancer Research 19, 258-267.
Bokemeyer, C., Bondarenko, I., Hartmann, J., De Braud, F., Schuch, G., Zubel, A., Celik, I., Schlichting, M., and Koralewski, P. (2011). Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Annals of Oncology 22, 1535-1546.
Bokemeyer, C., Bondarenko, I., Makhson, A., Hartmann, J. T., Aparicio, J., De Braud, F., Donea, S., Ludwig, H., Schuch, G., and Stroh, C. (2008). Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol.
Cassidy, J., Clarke, S., Diaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Rittweger, K., Gilberg, F., and Saltz, L. (2011). XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. British journal of cancer 105, 58.
Chow, F. C.-L., and Chok, K. S.-H. (2019). Colorectal liver metastases: An update on multidisciplinary approach. World journal of hepatology 11, 150.
Colucci, G., Gebbia, V., Paoletti, G., Giuliani, F., Caruso, M., Gebbia, N., Cartenì, G., Agostara, B., Pezzella, G., and Manzione, L. (2005). Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. Journal of Clinical Oncology 23, 4866-4875.
Cremolini, C., Loupakis, F., Antoniotti, C., Lupi, C., Sensi, E., Lonardi, S., Mezi, S., Tomasello, G., Ronzoni, M., and Zaniboni, A. (2015). FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. The Lancet Oncology 16, 1306-1315.
Díaz-Rubio, E., Tabernero, J., Gómez-Espana, A., Massutí, B., Sastre, J., Chaves, M., Abad, A., Carrato, A., Queralt, B., and Reina, J. J. (2007). Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish. Journal of Clinical Oncology 25, 4224-4230.
Douillard, J. Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., and Jassem, J. (2014). Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Annals of Oncology 25, 1346-1355.
Ducreux, M., Adenis, A., Pignon, J.-P., François, E., Chauffert, B., Ichanté, J., Boucher, E., Ychou, M., Pierga, J.-Y., and Montoto-Grillot, C. (2013). Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study). European Journal of Cancer 49, 1236-1245.
Ducreux, M., Bennouna, J., Hebbar, M., Ychou, M., Lledo, G., Conroy, T., Adenis, A., Faroux, R., Rebischung, C., and Bergougnoux, L. (2011). Capecitabine plus oxaliplatin (XELOX) versus 5‐fluorouracil/leucovorin plus oxaliplatin (FOLFOX‐6) as first‐line treatment for metastatic colorectal cancer. International journal of cancer 128, 682-690.
Falcone, A., Ricci, S., Brunetti, I., Pfanner, E., Allegrini, G., Barbara, C., Crino, L., Benedetti, G., Evangelista, W., and Fanchini, L. (2007). Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. Journal of Clinical Oncology 25, 1670-1676.
Folprecht, G., Gruenberger, T., Bechstein, W., Raab, H.-R., Weitz, J., Lordick, F., Hartmann, J., Stoehlmacher-Williams, J., Lang, H., and Trarbach, T. (2014). Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Annals of Oncology 25, 1018-1025.
Fuchs, C. S., Marshall, J., Mitchell, E., Wierzbicki, R., Ganju, V., Jeffery, M., Schulz, J., Richards, D., Soufi-Mahjoubi, R., and Wang, B. (2007). Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. Journal of Clinical Oncology 25, 4779-4786.
García‐Carbonero, R., van Cutsem, E., Rivera, F., Jassem, J., Gore, I., Tebbutt, N., Braiteh, F., Argiles, G., Wainberg, Z. A., and Funke, R. (2017). Randomized phase II trial of parsatuzumab (anti‐EGFL7) or placebo in combination with FOLFOX and bevacizumab for first‐line metastatic colorectal cancer. The oncologist 22, 375-e330.
Giantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., and Benson, A. r. (2007). Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. Journal of Clinical Oncology 25, 1539.
Giuliani, F., Vita, F. D., Maiello, E., Nugnes, I., Bisceglie, M. D., Romito, S., Lorusso, V., Catalano, G., Agostara, B., and Colucci, G. Folfiri versus xeliri in untreated advanced colorectal cancer: A phase II randomised trial of the Gruppo Oncologico dell’ Italia Meridionale (prot. GOIM 2405). 6, 120-121.
Green, S. (2011). Cochrane handbook for systematic reviews of interventions version 5.1. 0 [updated March 2011]. The Cochrane Collaboration.
Guyot, P., Ades, A., Ouwens, M. J., and Welton, N. J. (2012). Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC medical research methodology 12, 9.
Hammond, W. A., Swaika, A., and Mody, K. (2016). Pharmacologic resistance in colorectal cancer: a review. Therapeutic advances in medical oncology 8, 57-84.
Hegde, S. R., Sun, W., and Lynch, J. P. (2008). Systemic and targeted therapy for advanced colon cancer. Expert review of gastroenterology & hepatology 2, 135-149.
Heinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., and Seipelt, G. (2014). FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. The lancet oncology 15, 1065-1075.
Higgins, J. (2013). Identifying and addressing inconsistency in network meta-analysis. Cochrane comparing multiple interventions methods group Oxford training event 2013.
Higgins, J. P., and Altman, D. G. (2008). Assessing risk of bias in included studies. Cochrane handbook for systematic reviews of interventions: Cochrane book series, 187-241.
Higgins, J. P., and Thompson, S. G. (2002). Quantifying heterogeneity in a meta‐analysis. Statistics in medicine 21, 1539-1558.
Hochster, H. S., Hart, L. L., Ramanathan, R. K., Childs, B. H., Hainsworth, J. D., Cohn, A. L., Wong, L., Fehrenbacher, L., Abubakr, Y., and Saif, M. W. (2008). Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. Journal of Clinical Oncology 26, 3523-3529.
Hurwitz, H. I., Tan, B. R., Reeves, J. A., Xiong, H., Somer, B., Lenz, H. J., Hochster, H. S., Scappaticci, F., Palma, J. F., and Price, R. (2019). Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI‐Bevacizumab Versus FOLFOX‐Bevacizumab for Metastatic Colorectal Cancer (STEAM). The oncologist 24, 921-932.
Infante, J. R., Reid, T. R., Cohn, A. L., Edenfield, W. J., Cescon, T. P., Hamm, J. T., Malik, I. A., Rado, T. A., McGee, P. J., and Richards, D. A. (2013). Axitinib and/or bevacizumab with modified FOLFOX‐6 as first‐line therapy for metastatic colorectal cancer: A randomized phase 2 study. Cancer 119, 2555-2563.
Kim, S. T., Hong, Y. S., Lim, H. Y., Lee, J., Kim, T. W., Kim, K.-P., Kim, S. Y., Baek, J. Y., Kim, J. H., and Lee, K.-W. (2014). S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial. BMC cancer 14, 883.
Loupakis, F., Cremolini, C., Masi, G., Lonardi, S., Zagonel, V., Salvatore, L., Cortesi, E., Tomasello, G., Ronzoni, M., and Spadi, R. (2014). Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. New England Journal of Medicine 371, 1609-1618.
Oki, E., Kato, T., Bando, H., Yoshino, T., Muro, K., Taniguchi, H., Kagawa, Y., Yamazaki, K., Yamaguchi, T., and Tsuji, A. (2018). A multicenter clinical phase II study of FOLFOXIRI plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: QUATTRO study. Clinical colorectal cancer 17, 147-155.
Park, J., Kim, T., Lee, K., Han, S., Oh, D., Im, S., Kang, G., Chie, E., Ha, S., and Jeong, S. (2013). The beneficial effect of palliative resection in metastatic colorectal cancer. British journal of cancer 108, 1425.
Pectasides, D., Papaxoinis, G., Kalogeras, K. T., Eleftheraki, A. G., Xanthakis, I., Makatsoris, T., Samantas, E., Varthalitis, I., Papakostas, P., and Nikitas, N. (2012). XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis. BMC cancer 12, 271.
Porschen, R., Arkenau, H.-T., Kubicka, S., Greil, R., Seufferlein, T., Freier, W., Kretzschmar, A., Graeven, U., Grothey, A., and Hinke, A. (2007). Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. Journal of Clinical Oncology 25, 4217-4223.
Salanti, G., Ades, A., and Ioannidis, J. P. (2011). Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. Journal of clinical epidemiology 64, 163-171.
Saltz, L. B., Meropol, N. J., Loehrer Sr, P. J., Needle, M. N., Kopit, J., and Mayer, R. J. (2004). Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. Journal of clinical oncology 22, 1201-1208.
Sastre, J., Vieitez, J. M., Gomez-España, M. A., Gil Calle, S., Salud Salvia, A., Suárez, B. G., Garcia-Alfonso, P., Martinez de Castro, E., Quintero Aldana, G. A., and Reina-Zoilo, J. J. (2019). Randomized phase III study comparing FOLFOX+ bevacizumab versus folfoxiri+ bevacizumab (BEV) as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with≥ 3 baseline circulating tumor cells (bCTCs). In, (American Society of Clinical Oncology).
Soda, H., Maeda, H., Hasegawa, J., Takahashi, T., Hazama, S., Fukunaga, M., Kono, E., Kotaka, M., Sakamoto, J., and Nagata, N. (2015). Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study. BMC cancer 15, 695.
Souglakos, J., Androulakis, N., Syrigos, K., Polyzos, A., Ziras, N., Athanasiadis, A., Kakolyris, S., Tsousis, S., Kouroussis, C., and Vamvakas, L. (2006). FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). British journal of cancer 94, 798.
Souglakos, J., Ziras, N., Kakolyris, S., Boukovinas, I., Kentepozidis, N., Makrantonakis, P., Xynogalos, S., Christophyllakis, C., Kouroussis, C., and Vamvakas, L. (2012). Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC). British journal of cancer 106, 453.
Tol, J., Koopman, M., Cats, A., Rodenburg, C. J., Creemers, G. J., Schrama, J. G., Erdkamp, F. L., Vos, A. H., Van Groeningen, C. J., and Sinnige, H. A. (2009). Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. New England Journal of Medicine 360, 563-572.
Tomasello, G., Petrelli, F., Ghidini, M., Russo, A., Passalacqua, R., and Barni, S. (2017). FOLFOXIRI plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer: a systematic review and pooled analysis. JAMA oncology 3, e170278-e170278.
Van Cutsem, E., Kohne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., and Tejpar, S. (2011). Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J clin Oncol 29, 2011-2019.